Phio Pharmaceuticals announced progress on its Phase 1b clinical study for their lead compound PH-762. Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going. Phio‘s Phase 1b study is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study will assess the tumor response, and determine the recommended dose for further study of PH-762. “This is exciting news for Phio and our lead compound PH-762 with the dosing of the 1st cohort completed, we look forward to advancing the study to bring an innovative treatment option to patients with skin carcinomas,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHIO:
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
- Biotech Alert: Searches spiking for these stocks today
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)